Lexicon Pharmaceuticals, Inc. (LXRX)
2.04
+0.09
(+4.62%)
USD |
NASDAQ |
Jun 17, 16:00
2.035
0.00 (0.00%)
After-Hours: 20:00
Lexicon Pharmaceuticals Enterprise Value : 751.55M for June 17, 2026
Enterprise Value Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Enterprise Value Data
| Date | Value |
|---|---|
| June 17, 2026 | 751.55M |
| June 16, 2026 | 713.41M |
| June 15, 2026 | 717.65M |
| June 12, 2026 | 700.70M |
| June 11, 2026 | 687.99M |
| June 10, 2026 | 683.75M |
| June 09, 2026 | 683.75M |
| June 08, 2026 | 683.75M |
| June 05, 2026 | 696.46M |
| June 04, 2026 | 692.22M |
| June 03, 2026 | 671.04M |
| June 02, 2026 | 687.99M |
| June 01, 2026 | 764.27M |
| May 29, 2026 | 810.88M |
| May 28, 2026 | 823.60M |
| May 27, 2026 | 806.64M |
| May 26, 2026 | 760.03M |
| May 22, 2026 | 802.41M |
| May 21, 2026 | 832.07M |
| May 20, 2026 | 823.60M |
| May 19, 2026 | 789.69M |
| May 18, 2026 | 793.93M |
| May 15, 2026 | 832.07M |
| May 14, 2026 | 874.45M |
| May 13, 2026 | 921.06M |
| Date | Value |
|---|---|
| May 12, 2026 | 908.35M |
| May 11, 2026 | 865.97M |
| May 08, 2026 | 734.60M |
| May 07, 2026 | 598.99M |
| May 06, 2026 | 565.09M |
| May 05, 2026 | 586.28M |
| May 04, 2026 | 565.09M |
| May 01, 2026 | 577.81M |
| April 30, 2026 | 569.33M |
| April 29, 2026 | 543.90M |
| April 28, 2026 | 590.52M |
| April 27, 2026 | 603.23M |
| April 24, 2026 | 598.99M |
| April 23, 2026 | 598.99M |
| April 22, 2026 | 658.32M |
| April 21, 2026 | 662.56M |
| April 20, 2026 | 666.80M |
| April 17, 2026 | 679.51M |
| April 16, 2026 | 666.80M |
| April 15, 2026 | 675.27M |
| April 14, 2026 | 628.66M |
| April 13, 2026 | 611.71M |
| April 10, 2026 | 615.95M |
| April 09, 2026 | 632.90M |
| April 08, 2026 | 594.76M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Novo Nordisk A/S | 165.86B |
| Viatris, Inc. | 30.67B |
| Pfizer Inc. | 199.40B |
| ANI Pharmaceuticals, Inc. | 2.131B |
| Corcept Therapeutics, Inc. | 8.446B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -1.043M |
| Revenue (Quarterly) | 21.10M |
| Total Expenses (Quarterly) | 22.14M |
| EPS Diluted (Quarterly) | -0.0026 |
| Gross Profit Margin (Quarterly) | 98.97% |
| Profit Margin (Quarterly) | -4.94% |
| Earnings Yield | -3.50% |
| Normalized Earnings Yield | -3.505 |